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Objectives. This study was designed to determine whether 
maintenance of patency in coronary arteries with high grade 
stenosis after thrombolysis with tissue-type pIaS ’ 
requires inbib~tiom of tb~mb~~ 
Background. Activation of 
ilnplicated in delaying coronary recanaiiiation induced with 
d in 
(1.5 
or both, was given conjunctwely 
vator On 28 comxious 
tissue-ty 
Resrrlts. Among 22 dogs exhibiting coronary ~a~ali~t~o~, 
hirudin plus aspirin, but neither agent &me, modestly s~o~ene~ 
the interval tc, reczmalization (31 f 4 tin with saline solution, n = 
6; 29 * 4 min with aspirin, n= 5; 23 it: 9 min with hirudin, a= 
6; 21 f 7 min with hirudin + aspirin, n = 5). l&occlusion 
Widespread use of intravenous thrombolytic agents has 
redvced morbidity and mortality in patients with acute 
myocardial infarction (I ,2). Nevertheless, this approach is
limited by the f&lllrp to induce recanalization n as many as . .._ . . . . U._ 
30% of treated patients, delays in the induction f recanali- 
zation of rt h and the occurrence of early thrombotic 
reocclusion i  initially recandized vessels in as many as 20% 
of patients (3). Contributing tothese limitations i ongoing 
activation ofthrombin and platelets induced, in part, by the 
thrombolytic as&s (4-6). 
coagulation system that may facilitate thrombolysis and 
maintain patency without markedly perturbing hemostasis. 
Inhibition of thrombin sparticularly attractive b cause ofits 
powerful effects as a platelet agonist as well as a procoagu- 
lant molecule that converts fibrinogen to fibrin. 
Administration f either aspirin or heparin concomitantly 
with thromboiytic agents has been shown to enhance throm- 
bolysis in some (1,7,8) but not all clinical studies (g-11). 
Both agents may increase the risk of bleedihlg. Accordingly, 
interest has focused on novel inhibitors of platelets and the 
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We (12) have shown that direct inhibition of tbrom~i~ 
with recombinant desulfatohirudin (CGP 39393, hirudin) 
accelerates recanalization and prevents reoccluding platelet- 
rich thrombosis incanine coronary arteries without s per- 
imposed stenoses. It is not clear, however, whether inhibi- 
tion of thrombin alone is sufficient to accelerate 
recanalization a d prevent reocclusion when high grade 
stel,.4s, typical of that encountered clinicaIly (I3), is 
present as well. Accordingly, this study was performed to 
determine whether inhibition of thrombin with hirudin or 
combined inhibition of thrombin and platelets with hirudin 
and aspirin given conjunctively with recombinant tissue-type 
plasminogen activator ( t=FA) accelerates thrombolysis and 
attenuates arly, thrombotic reocclusion i canine coronary 
arteries with high grade stenoses. 
Animal preparations. Male mongrel dogs between 6 
months and 2 years of age and weighing 20 to 25 kg were 
@t993 by the American College ut Cardiology 07351097/93/56.W 
r descem~im~ coronary artcry. The 
were trimmed until their a~~os~t~~~ 
robe, a needle lect 
sutured to the ~~~card~~m. A ground wire was sutured to the 
~mt~~costa~ muscles. The wires were brought hrougffi the 
chest wall and were ~~~~e~e~ su 
em and eva6~lated 
in the left carotid 
ere performed unde 
guidelines of the American 
with intravenous 
of direct current through the coronary electrode co 
in series with the positive terminal of a 9-V battery, 
resistor, a59-l& potentiometer and an ammeter. Application 
of current was continued 5 min after c thrombotic 
occlusion had occurred, ected by the nce Of zero 
flow velocity. 
Before each study, dogs were assigned randomly to one 
of four treatment groups: group 1 In = 7) received saline 
solution (control); group 2 (n = 7) received aspirin (5 m&g 
boius of lysine acetyjlsahcyh.. r acid, a water-soluble anal0gue 
of aspirin) (Lorex pharmaceuticals); group 3 (n = 7) received 
hirudin (1.5 mgkg bohus foi~owed by I .5 mgkg per h of 
recoubinant d~s~i~fatob~rudi~, @GP 39393) (Ciba Geigy and 
CEN Therapeutica), nd group 4 (n = 7) received combined 
aspirin and hirudin. The doses and intervals ef administra- 
tion saf agents were selected to be those that completely 
occurred and be fore c~~~rne~cerne~~ 
to detect he 06 
velocity was moni- 
cc~~s~~~ (deemed as 
on 0%‘ Ihe extent 
terized ~~sto~og~cal~y and by 
after the corn~~~t~o~ of the i~~~s~o~ of 
serial assays. 
~r0t~rombi~ time and activated partial t
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Table 1. Intervals to Induction of Initial Coronary Occhision, Recanalization and 
Time to Occluhn Time to Time to Reocclusion 
After Onset of Recanaiization After After Start of 
Study Group/Conjunctive Electrical Stimulation Start of Infusion of Infusion of rt-PA 
Agent (min) &PA (min) (min) 
l/Saline solution (control) 44 ? 15 (n = 7) 31 k 4 (n = 6) 63 + IO (n = 5) 
2IAspirin 45 + 24 (n = 7) 29 t 4 (n = 5) 45 + IO (n = 5) 
3IHirudin 111~58(n=7) 23 f. 9 (n = 6) 67 f 32 (n = 4) 
4lHirudin t aspirin 43 I?r 17 (n = 7) 21 ?: 7 (n = 5) Reocclusion did not 
occur 
Values are expressed as mean values + SEM. r&PA = recombinant tissue-type plasminogen activator. 
to obtain 2.mm-thick segments of the vessel both proximal to 
the Doppler probe and in the region of stenosis. Segments 
were cut into !+rn sections and stained with hematoxyiin- 
eosin. Lumen areas were measured planimetricaiiy in dupli- 
cate and the percent area reduction was expressed as the 
ratio of the average area in the stenotic segment to the 
average area in the immediately proximal segment. 
To characterize the composition of residual thrombi, 
arteries were prepared for scanning clcctron microscopy, as 
described previously (12). In brief, the vessel and the Tygon- 
constricted segment were incised iongitudinahy. A pofiion 
of each was removed to expose the electrode, the vessel wail 
and any associated thrombus. The tissue was rinsed in 
cacodyiate buffer, postfixed in osmium tetroxide, dehy- 
drated in a series of ethanol solutions and critical-point dried 
with Peidr! II (Peiia). Specimens were sputter-coated with
chrome and gold-palladium and examined with a tiitachi 
S450 scanning electron microscope. 
Statistical analysis. Results are expressed asmean value 
k SEM. Between-treatment group differences were com- 
pared by analysis of variance. The Fisher exact est was 
used to compare the incidences of reocciusion between 
groups. A value of p 5 0.05 was considered significant. 
Passage ofelectrical current through the implanted coro- 
nary electrode induced thrombotic o clusion i 28 dogs. The 
interval from initiation of current to complete occlusion did 
not differ significantly among the four treatment groups 
(Table !), although it was delayed among dogs that later 
received hirudin alone by occlusion after 208 mi.1 in one dog. 
One dog in each of the groups randomized fortreatment with 
hirudin, aspirin and the combination f hirudin and aspirin 
exhibited spontaneous coronary recanaiization before infu- 
sion of agents and rt-PA could be initiated. These three dogs 
plus one dog that developed ventricular fibrillation after 
coronary occlusion were excluded from further analysis. 
Twenty-two f the remaining 24 dogs given r&PA and 
conjunctive agents exhibited arterial recanaiization, with 
return Of flow velocity to at least 50% of the baseline l vel. 
One dog given hirudin died before the completion of the 
observation i terval. Thus, 21 dogs were studied com- 
pletely. 
here was a trend 
tov ard more rapid recanaiization n dogs gven hirudin plus 
aspirin. Persistent reocciusion occurred in fiv 
control dogs given only saline solution with rt 
of five and four of five dogs given aspirin o 
rt-PA (Fig. 1). In contrast, reocclusion was 
dogs gk;cn both aspkin and hirndin con< 
r&PA. 
cts of ~o~~u~ctiv~ 
3. erali patency and 
dogs given both hirudin and aspirin co~jMnctive!y with 
rt-PA. Fewer episodes ofreocciusion compared with those 
in control dogs occurred uring ihe 2-h obs 
in dogs given aspirin; fewer still occurre 
hirudin (Fig. 2). Virtually no e 
ing for r! min were observed in dogs given both agents. 
Cyclic flow variations were also reduced significantly only in 
dogs given both aspirin and hirudin (2.4 +- 0.4/h with saline 
solution, 3.7 2 L.I/h with aspirin, 2.3 -I- 0.7/h with hirudin 
and 0.8 + 0.7/h with aspirin plus hirudin; p < 0.05 compared 
with values in control dogs). In dogs with patent arteries at 
the end of the 2-h observation i terval, blood flow velocity 
expressed asa percent of the average velocity before induc- 
tion of thrombosis was highest in dogs given both asplrin and 
Figure 1. Effects of conjunctive antithromboiic agents on the inci- 
dence of coronary eocclusion after initially successful thromboly- 
sis. *p < 0.05 compared with dogs given saline solution. 
Gontrol Aspirin Hirudin Hirudin 
Treatment 
Asiirin 
hirudin (32Y0 witl; saiine soiurion, n = 1; %i i l.5% with 
aspirin, n= 2; 44 -I- 26% with irudin, n = 2; 34 k 15% with 
arterles despite the previous pr 
ii-in; 43 k 1% with ~~r~d~~; 40 + 2% wit 
(1.0 2 0.P X 105/enm3 with saline solution; 1 .!J rf: 0.3 X 
IO’irmr~’ with aspirin; I.5 2 0.5 X W/mm3 with ~ir~d~~; 
1.2 + 0.3 X 105/mm3 with aspiri s hir~di~), except in 
dogs given both hirudin and aspiri 0.05 compared with 
baseline) because of high baseli ues in two animals 
(4.3 x 105/mm3 and 4.5 x I05/mm3) and because of a 
marked, unexplained decrease in platelet count in one other 
dog (0.5 x 105/mm3) after completion ofthe rt-P.,a infusion. 
The threshold concentration f collagen r 
uce aggregation f platelets in ~~ate~et-r~c~ 
reatly increased in dogs given aspirin or aspiri 
(from 6 + 4 and 5 k 4 pg/ml before admi~~istrat~o~ of the 
agents to r10 @g/ml afterward). misdid had no e 
threshold for aggregation of platelets induced by collagen. 
Administration of hirudin or hirudin plus aspirin pro- 
lc’nged the prothrombin time and the activated partial throm 
sectionval area t the sit 
emoostrated platelet aggrc- 
ante in patent vessels compared witb vesseis occiuded after 
24 h or between vessels from dogs in each of the coqjunctive 
treatment groups. 
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T&k 2. Effects of Conjunctive Agents on Hemostatic Variables 
Prothrombin ‘Time Partial Thromboplastin Time Heeding Time 
- 
,--. - 
I h After End I h After End I it After End 
“raseline of Infusion of Baseline of hfusion of BWZlill~ 01 Infusion of 
Coqhnhe Agent ts1 II-PA (s) (Sl rt-P4 6) (9 IT-PA (s) 
Saline solution (n = 4) 8.3 c 0.1 8.2 + 0.0 9.5 _; 0.2 9.6 + 0.6 I 16.8 k 28.0 109.8 I 36.5 
(1.0 + 0.0) (I.1 2 0.0) (0.9 2 0.3) 
Aspirin (n = 5) 8.2 c 0.0 8.3 f 0.1 10.2 r 0.6 9.2  0.5 109.2 k 20.4 86.2  17.5 
(1.0 2 0.0) (1.0 2 0.1) (0.9 -c 0.2) 
Hirudin (n = 5) 8.3 k O.@ 10.1 4 0.3 9.0 k 1.0 18.5 -c 0.7 112.2 +, 31.6 1z.3 c h6.7 
(1.2 2 0.0) (2.2 f 0.2) (1.3 + 0.2) 
Hirudin C aspfiir (n = Si 8.1 S 0.0 10.3 L 0.9 9.5 r I.2 22.3 1 2.7 121.1 2 33.6 152.7 + 24.9 
(1.3 % 0.1) (2.4 4 0.3) (1.6 t 0.3) 
___I-- .__I 
Values an expressed as mean value it SEM and, in parentheses, ratios between value obtained t h after the end of rt-PA infusion and the baseline value. 
ISPA = recombit& trssue-type plasminogen activator. _ 
antibodies against platelet glycoprotein IIbllIIa receptors i
only mrdestly effective in obviating these phenomena. RN- 
thermore, the doses required for even modest efficacy have 
oflen been so high that hemostasis has been grossly per- 
turbed (17). Platelet activation under these circumstances 
may be attributable to thrumbin, shown also to be generated 
by plasmin, and to other procoagulant moIecules released 
from thrombi undergoing lysis (4,18). Thus, inhibition or* 
thrombin may be particul&y important for facilitation of 
thrombolysis, In our previous tudies (12), conjunctive ad- 
ministration f recombinant hirudin with &PA consistently 
prevented reocclusion after thrombolysis in dogs with platelet- 
rich thrombi without concomitant high grade stenosis. 
Findings of this study. Results obtained in this study 
indicate that lysis of thrombi n vessels with associated 
severe stenosis, typical of conditions encountered clinically, 
is facilitated by inhibition of thrombin and by inhibition of 
platelets, as would be anticipated from previous observa- 
tions, However, they show that neither conjunctive inter- 
vention is sufficient alone to facilitate lysis and prevent 
reocclusion optimally when severe residual sta:nosis 
present (Fig. 1). Thus, under these circumstances both 
inhibition of thrombin and inhibition of platelets are re- 
quired. High grade stenosis may increase thrombin- 
independent activation of platelets mediated, in part, by 
exposure and activation of receptors for von Willebrdnd 
factor at high shear ates (19). 
These results are consistent with observations reported 
previously in studies of another direct hrombin inhibitor+ 
argatroban, combined with either a thromboxane A2antag- 
onist (20) oraspirin (21); however, such combinations may 
be iess effective than the one used in the present study, as 
judged from the persistent reocclusions and cyclic flow 
variations seen in some animals giveu argatroban d aspirin 
despite threefold elevations of partial thromboplastin me 
aps,d bleeding times (21). In our experiments with hirudin plus 
aspirin, no episodes ofpersistent reocclusion occurred (Fig. 
2). cycfic fiow variations were markedly and significantly 
reduced in dogs given both hirudin and aspirin at doses of 
both agents that increased the partial tbrorn~~p~~st~~~ time to 
only 2.4 times baseline value (that is, withirl a clinically 
accepted range). Bleeding time was increased ~wly 1h-f01 
(Table 21, 
The independent effect of heparin was not evaluated in
this study. We (12) and others (22,23) have shown that 
heparin doses that increase partial thrombo 
&s r*nrw of 2- t= 2,S-f# L..” I .-..a.# 
platelet-rich arterial thrombosis, even in the absence of 
concomitant high grade stenosis. Although studies compar- 
ing the effects of heparin and hirudin in patients are not yet 
dence on interaction with antithrombin Hil) and equivalently 
whether the thrombin sbound to fibrin or is free in solution 
(24-26). Hirudin has a high nity not only for thrombira 
(dissociation constant [I+,] = 2.3 x 1Q-‘4) but also for 
platelet thrombin receptors (IO- to lt00-fold higher than that 
exhibited by thrombin). Unlike heparin, hirudin can displace 
thrombin bound to platelet thrombin receptors (27). 
The experimental preparation used in this study exhibited 
platelet-rich reoccluding thrombi and coronary stenosis anal- 
ogous to those in patients with acute myocardial infarction 
(13,28). Utilization of a conscious dog preparation obviated 
potential distorting influences ofanesthesia and surgery on 
the behavior of the coagulation a d fibrinolytic systems and 
hence on results, It also enabled us to characterize coronary 
patency after 24 h. The finding of patent arteries after 24 h in 
the majotity of animals despite the presence of occlusion at 
2 h in some is consistent with intrinsic Gbrinolytic activity, 
which is known to be well developed indogs (“es). However, 
these results also suggest that a relatively brief exposure to 
antithrombotic agents may be sufficient to facilitate 
tained coronary patency after fhrombollysis, even 
underlying coronary stenosis i  severe. Of course, because 
both the fibrinolytic and the coagulation system in dogs are 
more active than those in humans (29), optimization ofthe 
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